Neumora Therapeutics

Update in progress

NMRA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. Its programs include navacaprant (NMRA-140), a once-daily oral kappa opioid receptor antagonist in Phase 3 for major depressive disorder; NMRA-511 in Phase 1b for agitation in Alzheimer's; NMRA-861 and NMRA-898, M4 muscarinic receptor PAMs for schizophrenia; and preclinical NMRA-GCase (PD), NMRA-CK1d (ALS), and NMRA-215 (NLRP3 inhibitor for obesity). Formerly RBNC Therapeutics, renamed in 2021. Founded 2019, based in Watertown, MA.

Company score

Sentiment: 0.17; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive